Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: A retrospective, nested case-controlled analysis

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 152-157

  Mohr III, John F ^a,d   Peymann, Patti J ^b   Troxell, Eric ^b   Lodise, Thomas P ^c   Ostrosky Zeichner, Luis ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HEALTHCARE SYSTEM   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

adverse events.; dysglycemia; fluoroquinolones; Gatifloxacin; hyperglycemia

Indexed keywords

CEFTRIAXONE; GATIFLOXACIN; GLUCOSE;

AGED; ANALYTIC METHOD; ARTICLE; CASE CONTROL STUDY; CLASSIFICATION; CLASSIFICATION AND REGRESSION TREE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TOTAL PARENTERAL NUTRITION; UNITED STATES; UNIVARIATE ANALYSIS;

ADRENAL CORTEX HORMONES; AGED; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 41149121025     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.009     Document Type: Article

References (18)

1. Menzies D., Dorsainvil P., Cunha B., and Johnson D. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 113 (2002) 232-234
2. Baker S., and Hangii M. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 36 (2002) 1722-1726
3. Biggs W. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 16 (2003) 455-457
4. Khovidhunkit W., and Sunthornyothin S. Hypoglycemia, hyperglycemia, and gatifloxacin. Ann Intern Med 141 (2004) 969
5. Blommel A., and Lutes R. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother 39 (2005) 1349-1352
6. Arce F., Bhasin R., and Pasmantier R. Severe hyperglycemia during gatifloxacin therapy in patients without diabetes. Endocr Pract 10 (2004) 40-44
7. Yip C., and Lee A. Gatifloxacin-induced hy-perglycemia: A case report and summary of the current literature. Clin Their 28 (2006) 1857-1866
8. Thompson C. Do not give gati-floxacin to diabetics. [ASHP Web site]. February 16, 2006. http://www.ashp.org/s_ashp/article_news.asp?CID=167&DID=2024&id= 14218. Accessed July 2, 2007.
9. Mohr J., McKinnon P., Peymann P., et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 25 (2005) 1303-1309
10. Park-Wyllie L., Juurlink D., Kopp A., et al. Outpatient gatifloxacin thera-py and dysglycemia in older adults. N Engl J Med 354 (2006) 1352-1361
11. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 41 (2005) 1269-1276
12. Yadav V., and Deopujari K. Gatifloxacin and dysglycemia in older adults. N Engl J Med 354 (2006) 2725-2726
13. http://clinicaltrials.gov/ct/show/ NCT00216385?order=2. Accessed January 9, 2008.
14. In: Zhang H., and Singer B. (Eds). Recursive Partitioning in the Health Sciences (1999), Springer, New York, NY
15. Magee M. Insulin therapy for intensive glycemic control in hospital patients. Hospital Physician (2006) 17-27
16. Ishiwata Y., Sanada Y., and Yasuhara M. Effects of gatifloxacin on serum glu-cose concentration in normal and diabetic rats. Biol Pharm Bull 29 (2006) 527-531
17. Tequin (gatifloxacin) [prescribing information] (2006), Bristol-Myers Squibb Company, Princeton, NJ
18. Ambrose P., Bhavnani S., Cirincione B., et al. Gatifloxacin and the elderly: Pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 52 (2003) 435-440